Ikervis ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 1 |
53. Sjogren syndrome
Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004929-33-AT (EUCTR) | 05/12/2018 | 27/11/2018 | Effect of Ciclosporin eyedrops on symptoms of the eye and visual quality in patients with dry eye syndrome and primary or secondary Sjögren syndrome | Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome | primary or secondary Sjögren Syndrome;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Ikervis Product Name: Ikervis INN or Proposed INN: CICLOSPORIN Trade Name: Softacort Product Name: Softacort INN or Proposed INN: HYDROCORTISONE SODIUM PHOSPHATE | KH Hietzing, Department of Ophthalmology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 4 | Austria |